I am asking mechanistically rather than practically — I want the model, not the protocol.
I would rather understand the derivation than memorise the outcome.
Two people I asked gave two answers that differ by a factor of ten, which is suggestive.
Can someone walk through the arithmetic step by step?
Answer first: the receptor is a class B G-protein-coupled receptor signalling mainly through Gs and cyclic AMP, and almost every downstream effect people ask about traces back to where that receptor is expressed rather than to what it does when activated.
Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.
Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.
The incretin effect itself was established by comparing the insulin response to oral and intravenous glucose loads matched for plasma glucose; the difference is what the gut hormones contribute.
The caveat is that mechanism predicts direction and rarely predicts magnitude in an individual, and people reason from mechanism to dose far too confidently.
Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe glucose-dependence is the key property. Below about four millimoles per litre the insulinotropic effect largely disappears, which is why monotherapy hypoglycaemia is uncommon.
Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.
Gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.
Nothing here is medical advice; this is pharmacology.
Mechanism is a good guide to what to expect and a poor guide to how much.
Answering this needs the distinction between the native hormone and the pharmacological agents, whose half-lives differ by three orders of magnitude and whose effects therefore differ in kind.
Glucagon suppression is also glucose-dependent and is lost during hypoglycaemia, which preserves the counter-regulatory response — a genuinely elegant piece of physiology and the reason the class is safe in this respect.
Central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.
The position-8 substitution conferring DPP-4 resistance appears in essentially every long-acting agent in the class, which is about as strong a piece of convergent evidence as medicinal chemistry offers.
A receptor being expressed in a tissue does not establish that activating it there matters at therapeutic exposures.
Nausea and appetite share an anatomy, which is why they are hard to separate by dose.
To be exact about it, the endogenous hormone is degraded by dipeptidyl peptidase-4 within a couple of minutes. Every long-acting agent in this class is essentially an answer to that one problem.
Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.
Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.
Research-use material is not approved for human use, and mechanism is not a safety argument.
Glucose-dependence is the property to remember; it explains the safety profile on its own.
The short version: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite effects, from one receptor in four places.
Biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.
Structural work on the receptor by cryo-electron microscopy has resolved the agonist-bound active state and is the basis for current structure-guided design in this class.
The caveat is that mechanism explains and does not predict. A clean mechanistic story has repeatedly failed to survive a Phase 3 in metabolic medicine.
The half-life problem and the albumin-binding solution are the whole story of the class chemically.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.